Caron A. Jacobson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Caron A. Jacobson has a total of 335 co-authors. Here are the top co-authors by number of shared publications:
- David Bernard Miklos
Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA
92 shared publications - Christina To
Kite, a Gilead Company, Santa Monica, California
70 shared publications - Simone Filosto
Kite, a Gilead Company, Santa Monica, California
70 shared publications - Frank Neumann
Kite, a Gilead Company, Santa Monica, California
58 shared publications - Jennifer Sun
Kite, a Gilead Company, Santa Monica, California
58 shared publications - Frederick L. Locke
Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida
55 shared publications
Latest Publications
- 23 September 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (12) , 3067-3071
Immune Effector Cell Therapies for Immune Thrombocytopenia Concurrent With Hematologic Malignancy
- 23 September 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (12) , 3067-3071
Immune Effector Cell Therapies for Immune Thrombocytopenia Concurrent With Hematologic Malignancy
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Purpose:Chimeric antigen receptor (CAR) T-cell therapies have improved outcomes in patients with relapsed/refractory large B-cell lymphoma (LBCL). However, up to two thirds of these patients do not maintain long-term responses. The phase 1/2 ZUMA-6 study investigated the feasibility of combining the CD19-directed CAR T-cell therapy axicabtagene ciloleucel (axi-cel) with the PD-L1 inhibitor atezolizumab as a potential approach to increase treatment efficacy while maintaining acceptable safety.Patients and Methods:Patients with refractory diffuse LBCL received a single axi-cel infusion (2 × 106 cells/kg), followed by atezolizumab 1,200 mg i.v. every 21 days for four cycles. Primary endpoints were dose-limiting toxicities (phase 1) and complete response rate (phase 2). Other efficacy and safety outcomes and pharmacokinetics/pharmacodynamics were assessed.Results:Overall, 34 patients received axi-cel plus atezolizumab in ZUMA-6. The median follow-up for the final analysis was 56.9 months. In phase 1, one patient experienced dose-limiting toxicities (grade 4 neutropenia and thrombocytopenia). Thirty patients (88%) experienced grade ≥3 treatment-emergent adverse events. Three (9%) and 11 (32%) patients experienced grade ≥3 cytokine release syndrome and neurologic events, respectively. In the final analysis, 15 patients (54%) had a complete response. The median progression-free survival and overall survival were 9 and 32.2 months, respectively. Peak CAR T-cell and cytokine profiles were comparable with those previously reported for axi-cel monotherapy (ZUMA-1).Conclusions:Axi-cel plus atezolizumab had a manageable safety profile, with no new safety signals. Safety and efficacy of this combination were consistent with axi-cel monotherapy. Correlative analyses could inform with regard to which patients with LBCL may benefit from axi-cel and immune checkpoint inhibitor combinations.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Purpose:Chimeric antigen receptor (CAR) T-cell therapies have improved outcomes in patients with relapsed/refractory large B-cell lymphoma (LBCL). However, up to two thirds of these patients do not maintain long-term responses. The phase 1/2 ZUMA-6 study investigated the feasibility of combining the CD19-directed CAR T-cell therapy axicabtagene ciloleucel (axi-cel) with the PD-L1 inhibitor atezolizumab as a potential approach to increase treatment efficacy while maintaining acceptable safety.Patients and Methods:Patients with refractory diffuse LBCL received a single axi-cel infusion (2 × 106 cells/kg), followed by atezolizumab 1,200 mg i.v. every 21 days for four cycles. Primary endpoints were dose-limiting toxicities (phase 1) and complete response rate (phase 2). Other efficacy and safety outcomes and pharmacokinetics/pharmacodynamics were assessed.Results:Overall, 34 patients received axi-cel plus atezolizumab in ZUMA-6. The median follow-up for the final analysis was 56.9 months. In phase 1, one patient experienced dose-limiting toxicities (grade 4 neutropenia and thrombocytopenia). Thirty patients (88%) experienced grade ≥3 treatment-emergent adverse events. Three (9%) and 11 (32%) patients experienced grade ≥3 cytokine release syndrome and neurologic events, respectively. In the final analysis, 15 patients (54%) had a complete response. The median progression-free survival and overall survival were 9 and 32.2 months, respectively. Peak CAR T-cell and cytokine profiles were comparable with those previously reported for axi-cel monotherapy (ZUMA-1).Conclusions:Axi-cel plus atezolizumab had a manageable safety profile, with no new safety signals. Safety and efficacy of this combination were consistent with axi-cel monotherapy. Correlative analyses could inform with regard to which patients with LBCL may benefit from axi-cel and immune checkpoint inhibitor combinations.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Axi-cel product characteristics
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Axi-cel product characteristics
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 9 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Correlation between pretreatment tumor PD-L1 H-score and baseline serum levels of soluble PD-L1
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 9 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Correlation between pretreatment tumor PD-L1 H-score and baseline serum levels of soluble PD-L1
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Serum biomarker analyte measurements
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Serum biomarker analyte measurements
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Axi-cel levels over time in patients with late CR conversions in Phase 1 Cohorts 1 and 2 and the mITT population (Phase 1 Cohort 3 and Phase 2)
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Axi-cel levels over time in patients with late CR conversions in Phase 1 Cohorts 1 and 2 and the mITT population (Phase 1 Cohort 3 and Phase 2)
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Grade ≥3 TEAEs present in ≥10% of patients at the primary analysis
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Grade ≥3 TEAEs present in ≥10% of patients at the primary analysis
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Phenotypic characterization of axi-cel products
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Phenotypic characterization of axi-cel products
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Representativeness of study participants
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Representativeness of study participants
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 6 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Serum peak biomarker associations with CRS and NEs in the final analysis
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 6 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Serum peak biomarker associations with CRS and NEs in the final analysis